Tag: BTKi

Long-term dual antiplatelet therapy does not increase mortality risk

Rilzabrutinib demonstrates rapid and durable clinical activity for immune thrombocytopenia

byDavid Xiangand1 others

April 22, 2022

1. Rilzabrutinib was active and 400mg twice daily was identified as the dose for further testing with low-level toxic effects. ...

#VisualAbstract Acalabrutinib monotherapy has acceptable tolerability and limited response in patients with Richter transformation

byKathleen Lau

November 11, 2021

#VisualAbstract Ibrutinib may be beneficial in heavily pretreated patients with classic and variant hairy cell leukemia

byKathleen Lau

July 8, 2021

#VisualAbstract Phase 2 trial shows umbralisib is safe and effective in patients with chronic lymphocytic leukemia who are intolerant to BTK or PI3Kδ inhibitor therapy

byKathleen Lau

June 4, 2021

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result